HC Wainwright Brokers Increase Earnings Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at HC Wainwright boosted their Q3 2024 earnings estimates for TScan Therapeutics in a report issued on Tuesday, August 13th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.36). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.24) EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.20) EPS.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. TScan Therapeutics had a negative return on equity of 61.13% and a negative net margin of 653.50%.

Several other equities analysts have also recently weighed in on TCRX. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research note on Monday, August 12th. Wedbush reiterated an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research report on Monday, August 12th. Finally, BTIG Research started coverage on shares of TScan Therapeutics in a research note on Thursday, May 16th. They set a “buy” rating and a $12.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Down 0.9 %

TCRX stock opened at $5.74 on Thursday. The company has a market cap of $303.43 million, a price-to-earnings ratio of -4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.23 and a current ratio of 5.23. The business’s 50-day moving average is $6.70 and its two-hundred day moving average is $7.15. TScan Therapeutics has a fifty-two week low of $1.97 and a fifty-two week high of $9.69.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP purchased a new position in TScan Therapeutics during the second quarter valued at approximately $70,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $90,000. Pale Fire Capital SE lifted its stake in shares of TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after buying an additional 4,998 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in TScan Therapeutics in the 2nd quarter worth $134,000. Finally, Cannon Global Investment Management LLC purchased a new stake in TScan Therapeutics in the 1st quarter worth $139,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.